Answer
In patients with advanced melanoma, ipilimumab has a mean terminal half-life of 15.4 days (coefficient of variation 34.4%), based on population pharmacokinetic analysis.
Sources for this answer
- YERVOY 5 mg/ml concentrate for solution for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 47Document updated
Sources checked